Skip to main content

Table 1 Characteristics of the included studies in which women with newly diagnosed ovarian cancer underwent front-line chemotherapy

From: Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis

Authors

Design

Population

Number of participants

Treatment arms

PFS

Number of adverse events (grade ≥ 3)

HR

95% CI

P value

Burger et al. (2011) [7], GOG 218

RCT, Phase 3

Overall population with ovarian cancer

(Serous type: 85%, stage III: 74.5%, stage IV: 25.5%)

Bevacizumab: 625

Control: 623

Bevacizumab: (Carboplatin AUC6 + Paclitaxel 175 mg/m2) q21 × 6 cycles

+ Bevacizumab 15 mg/kg q21 for cycles 2 through 22

Control: (Carboplatin AUC6 + Paclitaxel 175 mg/m2 + Placebo) q21 × 6 cycles

+ Placebo maintenance

* Bevacizumab or placebo was initiated at cycle 2, rather than cycle 1.

0.717

0.625–0.824

< 0.001

Bevacizumab: 408/607

Control: 356/608

Perren et al. (2011) [8], ICON 7

RCT, Phase 3

Overall population with ovarian cancer

(Serous type: 69%, stage I, II: 18.4%, stage III: 68.4%, stage IV: 13.2%)

Bevacizumab: 764

Control: 764

Bevacizumab: (Carboplatin AUC5 or 6 + Paclitaxel 175 mg/m2) q21 × 6 cycles + Bevacizumab 7.5 mg/kg q21 concurrently for 5 or 6 cycles and continued for 12 additional cycles or until PD

Control: (Carboplatin AUC5 or 6 + Paclitaxel 175 mg/m2) q21 × 6 cycles

* Bevacizumab was omitted at cycle 1 if chemotherapy was started within 4 weeks

of surgery

0.81

0.70–0.94

0.004

Bevacizumab: 491/745

Control: 419/753

Moore et al. (2018) [17], SOLO1

RCT, Phase 3

BRCAm cohort

(High grade serous type: 96%, stage III: 83.1%, stage IV: 16.9%)

PARPi: 260

Control: 131

Eligibility: Women who had a complete or partial clinical response after platinum-based chemotherapy

Randomization: After completion of platinum-based chemotherapy

PARPi: Oral Olaparib 300 mg twice daily until PD

Control: Placebo

0.3

0.23–0.41

< 0.001

PARPi: 208/260

Control: 42/130

González-Martín et al. (2019) [18], PRIMA

RCT, Phase 3

Overall population with ovarian cancer

(Serous type: 95%, stage III: 64.9%, stage IV: 35.1%)

PARPi: 487

Control: 246

Eligibility: Women who had a complete or partial clinical response after platinum-based chemotherapy

Randomization: Within 12 weeks after completion of the last dose of platinum-based chemotherapy

PARPi: Oral Niraparib 300 mg once daily in 28-day cycles for 36 months or until PD (200 mg in some cases)

Control: Placebo

0.62

0.5–0.76

< 0.001

PARPi: 341/484

Control: 46/244

BRCAm cohort

PARPi: 152

Control: 71

0.4

0.27–0.62

  

HRD cohort

(Serous type: 93.8%, stage III: 64.1%, stage IV: 35.9%)

PARPi: 247

Control: 126

0.43

0.31–0.59

< 0.001

 

Coleman et al. (2019) [19], VELIA

RCT, Phase 3

Overall population with ovarian cancer

(High grade serous type: 100%, stage III: 77.6%, stage IV: 22.4%)

PARPi: 382

Control: 375

PARPi: Carboplatin (AUC6, q21) + Paclitaxel (175 mg/m2 q21 or 80 mg/m2 q7) + oral Veliparib (150 mg twice daily) × 6 cycles followed by oral Veliparib 300 mg twice daily for 14 days and then oral Veliparib 400 mg twice daily until PD

Control: Carboplatin (AUC6, q21) + Paclitaxel (175 mg/m2 q21 or 80 mg/m2 q7) + Placebo × 6 cycles + Placebo maintenance

0.68

0.56–0.83

< 0.001

PARPi: 332/377

Control: 285/371

BRCAm cohort

(stage III: 79.5%, stage IV: 20.5%)

PARPi: 108

Control: 90

0.44

0.28–0.68

< 0.001

 

HRD cohort

(stage III: 77.7%, stage IV: 22.3%)

PARPi: 214

Control: 207

0.57

0.43–0.76

< 0.001

 
  1. BRCAm BRCA1/2 mutations, CI Confidence interval, HR Hazard ratio, HRD Homologous-recombination deficiency, PARPi Poly (adenosine diphosphate [ADP]–ribose) polymerase inhibitor, PFS Progression-free survival, PD Progression of disease